20-F: Can-Fite Unveils Executive Compensation Policy and Files Annual Report

Can-Fite BioPharma details its compensation policy for officers and reports financial results for the year ended December 31, 2024, in its latest SEC filing.

Summary

• Can-Fite BioPharma has filed its 20-F, which includes details on executive compensation and the company's financial performance.
• The document outlines the company's compensation policy for officers, approved by the General Meeting on July 3, 2024, and last updated on November 29, 2023.
• The policy aims to retain and recruit senior executives, incentivize motivation, balance compensation components, and strengthen shareholder trust.
• The compensation structure includes fixed compensation, benefits, performance-dependent compensation (bonus), capital compensation, retirement conditions, and exemption, insurance, and indemnity.
• Maximum gross fixed compensation ranges from up to NIS 150,000 per month for the CEO to amounts stipulated in Compensation Regulations for Board members.
• Bonuses for officers can reach up to 12 monthly salaries for the CEO and Active Chairman, and up to 8 monthly salaries for VPs, based on company and personal targets.
• Capital compensation through options will not exceed 75% of the total fixed annual compensation for VPs, CEO, or Active Chairman.
• The document also includes an Executive Officer Clawback Policy to recover erroneously awarded compensation due to accounting restatements.
• The company's annual report indicates a net loss of approximately $7.9 million in 2024, $7.6 million in 2023, and $10.1 million in 2022, with an accumulated deficit of approximately $166.4 million as of December 31, 2024.
• As of December 31, 2024, the company had cash and cash equivalents of $4.8 million and short-term deposits of $3.1 million.
• In August 2024, Can-Fite raised approximately $5.0 million in gross proceeds from a warrant inducement and exercise transaction and entered into an At The Market Offering Agreement to sell approximately $3.06 million in gross proceeds as of March 31, 2025.
• The company's board of directors approved a contingency plan to continue operations, including cost reduction and reduced compensation for key management personnel until additional financing is obtained.
• The company's existing financial resources are projected to be sufficient to meet requirements for the next twelve months from the date of the annual report.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative information. The company has a well-defined compensation policy and has made progress in raising capital. However, it has a history of losses and faces significant risks and challenges in its business and regulatory environment.

Positives

• The compensation policy is designed to attract and retain senior executives and incentivize motivation.
• The company has a clawback policy in place to recover erroneously awarded compensation.
• Can-Fite has secured orphan drug designation for Namodenoson, which provides certain benefits.
• The company has a contingency plan in place to manage cash flow.
• The company's existing financial resources are projected to be sufficient to meet requirements for the next twelve months from the date of the annual report.

Negatives

• The company has incurred operating losses since its inception and anticipates continuing to incur substantial operating losses.
• The company will need to raise additional capital to meet its business requirements in the future.
• The company does not currently satisfy the NYSE American requirements for continued listing.
• The expiry of a patent that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had by virtue of this license may diminish our proprietary position.

Risks

• The company's product candidates are at various stages of clinical and preclinical development and may never be commercialized.
• Clinical trials are very expensive, time-consuming, and difficult to design and implement.
• The company depends on key members of its management and key consultants.
• The company conducts its operations in Israel, and its results may be adversely affected by political, economic, and military instability in Israel and its region.
• The market price of the company's ordinary shares and ADSs is subject to fluctuation.
• The company does not currently satisfy the NYSE American requirements for continued listing.

Future Outlook

The company expects to continue to expend substantial resources for the foreseeable future developing its product candidates and believes that its existing financial resources will be sufficient to meet its requirements for the next twelve months from the date of issuance of this Annual Report on Form 20-F.

Industry Context

The announcement highlights Can-Fite's position in the competitive biopharmaceutical industry, specifically in the areas of cancer, liver, and inflammatory diseases. The document mentions key competitors in these therapeutic areas, including Amgen, J&J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB, Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Gilead, Genfit, Galmed, Madrigal, Akero, 89Bio, Viking, and Terns. The company emphasizes the potential advantages of its drug candidates, such as oral administration, safety profile, and low cost of production, compared to existing treatments.

Comparison to Industry Standards

• The document mentions several competitors in the psoriasis therapeutic field, including Amgen, J&J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, and UCB.
• These companies have marketed products and/or advanced research and development pipelines in psoriasis.
• In the HCC field, competitors include Bayer, Exelixis, Merck, Roche, Eisai, Astrazenca, Beigene, Novartis, and Bristol-Myers Squibb.
• These companies have marketed products and/or advanced research and development pipelines in HCC.
• In the MASH field, competitors include Gilead, Genfit, Galmed, Madrigal, Akero, 89Bio, Viking, and Terns.
• These companies have marketed products and/or advanced research and development pipelines in MASH.
• In the pancreatic cancer field, competitors include Bristol-Myers Squibb and Ipsen.
• In the erectile dysfunction field, competitors include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.
• The document also notes that several companies have reported research projects related to the A3AR, including CV Therapeutics Inc. (acquired by Gilead), King Pharmaceuticals R&D Inv. (acquired by Pfizer), Hoechst Marion Roussel Inc. (acquired by Aventis), Novo Nordisk A/S, and Inotek Pharmaceuticals.

Related Party Transactions

• One of the company's directors is a senior partner in the patent firm which represents the company in intellectual property and commercial matters, or the Service Provider.
• The Service Provider charges the company for services it renders on an hourly basis.
• The aggregate amount of these expenses was approximately $285,000, $237,000 and $218,000 in 2024, 2023 and 2022, respectively.
• The company employs Zivit Harpaz as Director of Regulatory and Clinical Operations.
• For fiscal years 2024, 2023 and 2022, Ms. Harpaz received salary, bonus and benefits totaling approximately $270,000, $262,000 and $278,000, respectively.
• During fiscal years 2024, 2023 and 2022, the company awarded to Ms. Harpaz options to purchase 4,000,000, 3,000,000 and 1,250,000 ordinary shares, respectively.
• Ms. Harpaz is the daughter of Pnina Fishman.

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Shareholders are subject to market risk and potential losses from fluctuations in the share price.
• The company's ability to develop and commercialize its product candidates will impact its future financial performance and shareholder value.
• Employees may be affected by cost reduction measures and changes in compensation.
• Patients may benefit from the development of new and effective treatments for cancer, liver, and inflammatory diseases.

Next Steps

• Continue pivotal Phase III studies for Piclidenoson in psoriasis.
• Continue pivotal Phase III trial for Namodenoson in advanced liver cancer.
• Continue Phase IIb study of Namodenoson in MASH.
• Continue exploratory Phase II study of Namodenoson in pancreatic cancer.
• Undertake preparatory work for a Phase II study with Piclidenoson for the treatment of Lowe syndrome.
• Investigate additional compounds, targeting A3AR, for the treatment of erectile dysfunction.

Key Dates

Keywords

Compensation Policy, Financial Results, Can-Fite BioPharma, Annual Report, Piclidenoson, Namodenoson, Clinical Trials, Biopharmaceutical, Executive Pay, A3AR